Dudley, Mark E.
None , 🇺🇳
2024 Rank: 54150
Data For The Year: 2024
Main Field
Clinical Medicine
SubField 1
Immunology
SubField 2
Oncology & Carcinogenesis
Metrics
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 54150 | 62926 |
| Total Cites | 1981 | 2021 |
| H-index | 23 | 23 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 215 | 217 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 447 | 451 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1269 | 1279 |
| Ratio of Total Citations to Distinct Citing Papers | 1.56 | 1.58 |
| Self-Citation Percentage |
1.98%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Dudley, Mark E.
Novartis International AG , 🇺🇸
2023 Rank: 46238
Data For The Year: 2023
Main Field
Clinical Medicine
SubField 1
Immunology
SubField 2
Oncology & Carcinogenesis
Metrics
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 46238 | 51410 |
| Total Cites | 2205 | 2259 |
| H-index | 25 | 26 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 230 | 236 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 444 | 454 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1339 | 1359 |
| Ratio of Total Citations to Distinct Citing Papers | 1.65 | 1.66 |
| Self-Citation Percentage |
2.39%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Dudley, Mark E.
Novartis International AG , 🇺🇸
2022 Rank: 26603
Data For The Year: 2022
Main Field
Clinical Medicine
SubField 1
Immunology
SubField 2
Oncology & Carcinogenesis
Metrics
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 26603 | 29808 |
| Total Cites | 2592 | 2687 |
| H-index | 27 | 27 |
| Hm-index | 5 | 6 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 303 | 312 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 589 | 605 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1484 | 1502 |
| Ratio of Total Citations to Distinct Citing Papers | 1.75 | 1.79 |
| Self-Citation Percentage |
3.54%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Dudley, Mark E.
Novartis International AG , 🇺🇸
2021 Rank: 33163
Data For The Year: 2021
Main Field
Clinical Medicine
SubField 1
Immunology
SubField 2
Oncology & Carcinogenesis
Metrics
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 33163 | 38900 |
| Total Cites | 3914 | 4009 |
| H-index | 28 | 28 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 465 | 468 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 888 | 900 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2227 | 2255 |
| Ratio of Total Citations to Distinct Citing Papers | 1.76 | 1.78 |
| Self-Citation Percentage |
2.37%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Dudley, Mark E.
Novartis International AG , 🇺🇸
2020 Rank: 28647
Data For The Year: 2020
Main Field
Clinical Medicine
SubField 1
Immunology
SubField 2
Oncology & Carcinogenesis
Metrics
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 28647 | 32735 |
| Total Cites | 3095 | 3253 |
| H-index | 26 | 26 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 314 | 327 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 619 | 649 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1710 | 1749 |
| Ratio of Total Citations to Distinct Citing Papers | 1.81 | 1.86 |
| Self-Citation Percentage |
4.86%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Related Profiles
Advertise
📢 Advertise with us and reach a targeted audience of science enthusiasts and professionals.